Martinez-Usatorre et al. improved the efficacy of PD-1/PD-L1 inhibitors by modulating the tumor microenvironment in a KRASG12D/+;TP53−/− genetically engineered mouse model. This evidence concerns the gene CD274 and neoplasm.